Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBLGNASDAQ:CTCXNASDAQ:ICCMNASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$3.02+0.7%$4.65$2.87▼$25.50$1.68M0.69350,974 shs54,774 shsCTCXCarmell$2.35-3.7%$2.14$0.17▼$1.98$4.13M0.514.32 million shs20,236 shsICCMIceCure Medical$1.08+2.9%$1.03$0.48▼$1.66$59.67M0.31478,207 shs144,269 shsSURGSurgePays$3.42+3.5%$2.90$1.05▼$3.47$69.73M0.46627,314 shs45,365 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics-13.69%-25.56%-37.60%-27.54%-57.63%CTCXCarmell0.00%-5.79%-10.62%+1,933.33%+46.11%ICCMIceCure Medical-0.85%+5.47%+3.45%-1.87%+43.84%SURGSurgePays+2.33%+6.11%+17.44%+40.43%+10.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBLGBone Biologics1.0976 of 5 stars0.04.00.00.02.40.01.3CTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AICCMIceCure Medical2.0887 of 5 stars3.84.00.00.00.00.00.6SURGSurgePays3.0309 of 5 stars3.55.00.00.01.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLGBone Biologics 0.00N/AN/AN/ACTCXCarmell 0.00N/AN/AN/AICCMIceCure Medical 3.50Strong Buy$2.50131.48% UpsideSURGSurgePays 3.00Buy$9.00163.54% UpsideCurrent Analyst Ratings BreakdownLatest BBLG, SURG, ICCM, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.005/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.504/22/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.50 ➝ $8.75(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/ACTCXCarmell$32.84K1,495.99N/AN/A$1.07 per share2.20ICCMIceCure Medical$3.27M18.31N/AN/A$0.12 per share9.00SURGSurgePays$40.03M1.74N/AN/A$0.76 per share4.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)CTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)SURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)Latest BBLG, SURG, ICCM, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLGBone BiologicsN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLGBone BiologicsN/A12.6012.60CTCXCarmellN/A0.310.29ICCMIceCure Medical0.021.891.48SURGSurgePays0.241.721.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLGBone Biologics34.30%CTCXCarmell24.22%ICCMIceCure Medical0.62%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipBBLGBone Biologics7.50%CTCXCarmell29.00%ICCMIceCure Medical2.44%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLGBone Biologics2550,000504,000Not OptionableCTCXCarmell1420.91 million14.84 millionNot OptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableSURGSurgePays4020.41 million14.19 millionOptionableBBLG, SURG, ICCM, and CTCX HeadlinesRecent News About These CompaniesSurgePays Launches New PrePaid Service Smartphones Designed For Convenience Stores And Non-Wireless Retail ChannelsJuly 3, 2025 | twice.comTSurgePays (NASDAQ:SURG) Share Price Passes Above 200 Day Moving Average - Here's What HappenedJuly 2, 2025 | marketbeat.comGPOPlus+ Shareholder UpdateJune 30, 2025 | accessnewswire.comASurgePays launches prepaid phone-in-a-box service for convenience storesJune 27, 2025 | investing.comSurgePays Launches New Prepaid Service, "Phone-in-a-Box," Designed for Convenience Stores and Non-Wireless Retail ChannelsJune 26, 2025 | prnewswire.comSurgePays (NASDAQ:SURG) Share Price Crosses Above Two Hundred Day Moving Average - Here's WhyJune 24, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.00June 16, 2025 | marketbeat.comSurgePays to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25June 11, 2025 | prnewswire.comSurgePays Confirms Directors and Ratifies Accounting FirmMay 20, 2025 | tipranks.comAT&T (NYSE:T) Partners With Carbyne For APEX Continuity Emergency Solution For PSAPsMay 20, 2025 | finance.yahoo.comUS$8.75 - That's What Analysts Think SurgePays, Inc. (NASDAQ:SURG) Is Worth After These ResultsMay 17, 2025 | uk.finance.yahoo.comSurgePays Secures $7M Convertible Note for ExpansionMay 16, 2025 | tipranks.comWhy SurgePays, Inc.’s (SURG) Stock Is Down 19.64%May 15, 2025 | aaii.comAQ1 2025 Surgepays Inc Earnings CallMay 15, 2025 | uk.finance.yahoo.comSurgePays, Inc. (SURG) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comSurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comSurgePays Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comSurgePays Announces $7 Million Debt Financing to Accelerate GrowthMay 13, 2025 | prnewswire.comSurgePays to Host First Quarter 2025 Financial Results Conference Call on Tuesday, May 13thMay 6, 2025 | prnewswire.comEarnings Preview: SurgePays, Inc. (SURG) Q1 Earnings Expected to DeclineMay 5, 2025 | zacks.comPOS Fintech SurgePays Launches on AT&TApril 28, 2025 | crowdfundinsider.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceRocket Lab: Latest Catalysts Bolster the Bull CaseBy Ryan Hasson | July 3, 2025View Rocket Lab: Latest Catalysts Bolster the Bull CaseMarvell's New AI Chip Deals Capture Wall Street’s AttentionBy Jeffrey Neal Johnson | June 21, 2025View Marvell's New AI Chip Deals Capture Wall Street’s AttentionBBLG, SURG, ICCM, and CTCX Company DescriptionsBone Biologics NASDAQ:BBLG$3.02 +0.02 (+0.67%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Carmell NASDAQ:CTCX$2.35 -0.09 (-3.69%) As of 07/7/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.IceCure Medical NASDAQ:ICCM$1.08 +0.03 (+2.86%) As of 11:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.SurgePays NASDAQ:SURG$3.42 +0.12 (+3.48%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
